GLP-1 Receptor Agonists May Protect Kidney Health in Bipolar Disorder Patients

Mayo Clinic researchers have found that GLP-1 receptor agonists, medications commonly used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease. Published in the Journal of Clinical Psychiatry, this observational study suggests a potential added benefit of these medications in protecting kidney health within this high-risk population, though prospective studies are needed to confirm a direct causal link.